T-Therapeutics, a UK biotech developing next-generation T cell receptor (TCR) therapies for cancer and autoimmune diseases, has expanded its Series A round with an additional €27.5 million ($32 million) in funding.
New investors Tencent and BGF joined the syndicate, alongside returning backers Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, and the University of Cambridge Venture Fund.
This extension brings the total Series A to €78.2 million ($91 million), following the initial €50.7 million raised.
Transforming TCR Therapeutics
CEO Theodora Harold said:
“Our medicines target upstream disease drivers with the potential to impact multiple indications. This expanded financing reflects strong validation of our platform and progress. We are grateful for the confidence shown by both new and existing investors.”
Advertisement
A Major Player in Europe’s 2025 Immuno-Oncology Landscape
T-Therapeutics’ raise stands out in a year of growing European activity in immuno-oncology.
In France, Adcytherix secured €105 million, while Spain’s Adaptam Therapeutics raised €3 million for next-gen immunotherapies.
With roughly €108 million invested across the sector so far, T-Therapeutics’ €78.2 million represents one of the most significant rounds of the year, reinforcing the UK’s position as a leader in immune-driven drug development.
Sofinnova Partner Graziano Seghezzi commented:
“This new capital allows T-Therapeutics to expand into T-cell subset depletion—one of the most exciting frontiers in immunology—while progressing its oncology programmes. The platform unlocks targets long considered undruggable.”
Built on Cambridge Science and Deep Expertise
Spun out of the University of Cambridge in 2022, T-Therapeutics is engineering next-generation TCR (TTCR) therapeutics designed to safely and effectively modulate T-cell biology.
Its team combines capabilities across:
- mouse genome engineering
- single-cell genomics
- biopharmaceutical development
- machine learning
- structural biology
Its OpTiMus® platform produces a virtually unlimited library of highly specific, fully human TCRs, opening access to previously unreachable intracellular targets. These are paired with proprietary next-generation CD3 T cell engagers (TCEs) built for optimal potency, safety, and pharmacokinetics—forming the basis of a new class of bispecific drugs.
Driving First-in-Class Assets Toward the Clinic
The new funding will accelerate development across oncology and autoimmune indications, including emerging approaches such as targeted T-cell subset depletion.
Pipeline highlights include:
- Lead oncology asset targeting a pan-tumour driver present in multiple solid tumours
- Lead immunology programme: a pan-autoimmune bispecific designed to selectively eliminate pathogenic immune cells, enabling precision immune reset
BGF Partner Luke Rajah noted:
“This team has a proven track record turning breakthrough science into medicines. With world-class investors behind them, T-Therapeutics is uniquely positioned to unlock previously undruggable biology.”
About T-Therapeutics
T-Therapeutics, a University of Cambridge spin-out, is a next-generation TCR company developing optimized T-cell receptor therapeutics for cancer and autoimmune diseases. Powered by its OpTiMus® platform and fully humanized TCR mouse models, the company generates a vast repertoire of antigen-specific human TCRs to create first-in-class bispecific medicines.
